US20040162515A1 - Apparatus and method for out-of-hospital thrombolytic therapy - Google Patents
Apparatus and method for out-of-hospital thrombolytic therapy Download PDFInfo
- Publication number
- US20040162515A1 US20040162515A1 US10/750,503 US75050303A US2004162515A1 US 20040162515 A1 US20040162515 A1 US 20040162515A1 US 75050303 A US75050303 A US 75050303A US 2004162515 A1 US2004162515 A1 US 2004162515A1
- Authority
- US
- United States
- Prior art keywords
- drugs
- thrombolytic
- patient
- infusion
- hospital
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
- A61M5/1456—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons with a replaceable reservoir comprising a piston rod to be moved into the reservoir, e.g. the piston rod is part of the removable reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/1407—Infusion of two or more substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/145—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons
- A61M5/1452—Pressure infusion, e.g. using pumps using pressurised reservoirs, e.g. pressurised by means of pistons pressurised by means of pistons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/44—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests having means for cooling or heating the devices or media
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/002—Compounding apparatus specially for enteral or parenteral nutritive solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M2005/1401—Functional features
- A61M2005/1402—Priming
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3546—Range
- A61M2205/3553—Range remote, e.g. between patient's home and doctor's office
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/35—Communication
- A61M2205/3576—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver
- A61M2205/3584—Communication with non implanted data transmission devices, e.g. using external transmitter or receiver using modem, internet or bluetooth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/36—General characteristics of the apparatus related to heating or cooling
- A61M2205/3606—General characteristics of the apparatus related to heating or cooling cooled
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M39/00—Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
- A61M39/22—Valves or arrangement of valves
- A61M39/223—Multiway valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/142—Pressure infusion, e.g. using pumps
- A61M5/14244—Pressure infusion, e.g. using pumps adapted to be carried by the patient, e.g. portable on the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
Definitions
- This invention relates to medical devices and more particularly to devices and methods for thrombolytic therapy of coronary arteries for patients experiencing an early stage of acute myocardial infarction.
- Acute myocardial infarction is a major cause of mortality and morbidity in an atherosclerosis—prone contemporary society. Each year approximately 1.5 million Americans suffer a myocardial infarction, and more than 400,000 individuals will likely die from it this year. Few life threatening diseases are as common as acute myocardial infarction.
- Myocardial infarction is the morphologic manifestation of irreversible cell death in an area of the heart that is caused by a prolonged, and often abrupt, mismatch between the supply of the oxygen and nutrients in the blood and the metabolic needs of the myocardial cells. The most common cause of this condition is the sudden interruption of blood flow in a coronary artery by an occlusive thrombus formed in an area with atherosclerotic disease.
- a myocardial infarction is an evolving, dynamic event.
- a coronary occlusion results in ischemia that is initially reversible, but over time becomes irreversible.
- Necrosis of myocardium, or cardiac muscle begins 20 to 30 minutes after total occlusion of the vessel. This “wave front of necrosis” proceeds through the ischemic part of the myocardium and is complete within 4-6 hours of occlusion. Later a scar is formed over the necrotic part of the myocardium.
- the area of myocardium affected by infarction does not contribute any more to the overall pumping function of the heart.
- thrombolytic agents including streptokinase, urokinase, anisteplase, and tissue plasminogen activator (tPA) are extremely efficient in preventing disability and the death among people having heart attacks. About 80 percent of people having a heart attack who receive a thrombolytic agent within 2 hours of the onset of symptoms have reperfusion. Successful reperfusion reduces the size of the myocardial infarction and helps preserve the overall pumping function of the heart.
- tPA agent is about 10 times more expensive than streptokinase, but there is no difference in the time of dissolving of fresh thrombi.
- Nitroglycerin is given either under the tongue or by vein to reduce symptoms by decreasing the heart's demand for oxygen and by improving the blood flow through coronary arteries as much as possible.
- Heart attacks can be very painful, so narcotics such as morphine are given when necessary.
- Medications such as beta-adrenergic blocking agents may be helpful for reducing pain and enhancing survival.
- Beta-adrenergic blockers make the heart beat more slowly and less forcefully, so it requires less oxygen.
- Blood clots can re-form in the coronary artery at the sites where thrombolysis has already dissolved the original blood clot.
- Thrombolytic drugs dissolve blood clots that already formed; anticoagulants prevent new blood clots from developing.
- a similar function is performed by antiplatelet medication like aspirin, which can be administered orally or intravenously.
- the emergency care be selected, prescribed and managed by the patient's personal cardiologist, who is familiar with the patient's cardiac history and general state of health.
- An IV needle carrier assembly is described in U.S. Pat. No. 4,170,993. It includes a delta-shaped base plate and IV needle carrier—receiving barrel, secured to the base plate. An adhesion tape affixed to the base plate anchors the plate to the skin of the patient. The needle can be moved in two positions, rearward and forward. In the latter position it is placed for puncturing the vein. After establishing an IV access the base is affixed by the adhesion tape for the assembly to retain its place on the skin.
- This IV needle assembly is intended to be used by a medical professional and is not adapted to gaining an IV access by a patient himself.
- An object of the present invention is to provide an apparatus and method for intravenous infusion of thrombolytic agents and supportive medication as early as 20-30 minutes after the onset of the heart attack symptoms.
- Another object of the present invention is to provide an apparatus capable of being in a stand-by position continuously for several years.
- Yet another object of the invention is to provide numerous standard schedules of delivery of medications, enabling a cardiologist to select an appropriate care for covering the needs of different patients.
- Another object of the present invention is, in case of inability to promptly contact a personal cardiologist or other qualified physician, to provide a cardiac patient with an option to self-diagnose an acute myocardial infarction and self-administer the thrombolytic therapy.
- Another object of the present invention is to provide a simple and easy to use needle carrier adapted for gaining IV access by a patient himself or another person without special advanced medical training.
- Yet another object of the invention is to provide a low temperature environment for the library of medications ensuring preservation of their potency for several years.
- Yet another object of the present invention is to provide a library of medication for thrombolytic therapy and supportive care for the treatment of a heart attack.
- Provided medication can be in a lyophilized or liquid form.
- Another object of present invention is to provide to a personal cardiologist or other qualified physician remote access to the control of the apparatus via the Internet or other information network.
- Another object of the present invention is to provide an apparatus for IV infusion, that is highly automated and, after activation, does not require any intervention of an operator.
- Still another object is to make the system portable and battery powered, so it can be maintained in a stand by state at a residence, in a car, in an aircraft, or in the field.
- the fore mentioned objects are achieved by the present invention, which provides an apparatus and method for emergency treatment of a myocardial infarction.
- the apparatus comprises a library of medications, a highly automated infusion pump, controlled by a microprocessor, an intravenous needle, providing an access to the patient's circulatory system, a set of valves and conduits, providing fluid communication between the pump, the needle, the medications vials and a bag of solvent used for reconstitution of the lyophilized medications.
- These medications are placed into a sterile compartment, in which temperature is reduced to 4 C. or lower. This temperature guarantees protein thrombolytic drug stability during 3-5 years if the cooler is not off more than 1-3 months total.
- the invention is intended to be used in the out-of-hospital settings like a residence, a car, a passenger aircraft, a hotel, a nursing home and the like.
- This invention provides an opportunity to a patient himself to start the thrombolytic therapy right after the onset of cardiac pain, only 20-30 minutes after an occlusion in coronaries had been diagnosed (independently by the patient him/herself or after a consultation with a physician).
- the patient should perform very simple operations with a highly automated infusion system.
- the system reconstitutes the lyophilized drugs and primes itself by venting the air to avoid an air embolism.
- the system When the system is ready for infusion, it sends a message to the operator and waits for a command to start infusion.
- the patient should gain an IV access by puncturing a vein on his/her wrist, thereby fluidly connecting the infusion apparatus with the patient's circulatory system.
- the thrombolytic and concomitant therapy can be started at any moment.
- the system uses as a default a predetermined infusion schedule, preselected by a personal physician of the patient.
- the state of the patient during infusion can be evaluated by a physician via a phone line though conversation, or other diagnostic means like ECG with an Internet interface, capable of sending data to the physician.
- the system can be stopped at any moment and, depending on the state of the patient, the infusion schedule can be changed via the Internet by a qualified physician or by the operator (patient) directly.
- This invention is intended to be used by well-informed patients experiencing an early stage of a heart attack. Individuals who already had a heart attack, are good candidates for using the apparatus.
- the term well-informed patients means that these patients not only are familiar with the basics of the cardiovascular disease but also were instructed in details by their personal cardiologist how to use this apparatus, how to communicate with the physician during the onset of a heart attack, what symptoms are important for the correct diagnosis or self-diagnosis of his/her conditions, if by some reasons the contacts with a cardiologist are impossible. In this case the patient must rely upon his/her own judgments and an automated infusion of drugs which will be performed according to the schedules preselected by the patient's physician.
- the present invention provides thrombolytic therapy for cardiac patients at the earliest stage of a heart attack, before any necrosis of myocardium or other irreversible changes occur.
- the thrombus is weak and is easier to dissolve. It requires less time and amount of thrombolytic agent for restoring patency of the occluded artery and thus results in lower chances of bleeding complications, the major side effect of thrombolytic therapy.
- SK or t-PA thrombolytic drugs
- an early thrombus can be efficiently dissolved by a cheaper streptokinase (SK), cost of which is about 10% of that of t-PA.
- SK streptokinase
- the overall value of the present invention is provided by the ability of early TT to completely salvage patient's myocardium, resulting in significantly lower morbidity and mortality.
- the present invention is designated for use by emergency personal with limited or no medical training in nursing homes, passenger aircrafts and the like, and by well-informed high heart attack risk cardiac patients.
- the intended individual users should be cautiously screened by a qualified cardiologist before prescribing them an opportunity to buy a system and self-administering the thrombolytic drugs.
- individual users Before activating the system and starting TT individual users have to diagnose a coronary artery occlusion relying upon their symptoms.
- the pain of an acute MI typically lasts for at least 30 min, it is unrelenting and does not respond to nitroglycerin. Pain that is not relieved by nitroglycerin or nifedipine challenge (ruling out coronary vasospasm) would indicate occlusive thrombus instead of unstable angina.
- a needle carrier 1 which includes an IV needle 2 , is fluidly connected via a conduit 4 to an outlet 7 of a syringe 9 .
- Hydrophilic filter 5 prevents accidentally trapped air bubbles from entering the patient circulation.
- One-way valve 6 separates the needle conduit 4 from a conduit star junction 8 , connected to the syringe outlet 7 .
- the valve 6 has two positions: “on”, which allows the liquid from the syringe outlet 7 to flow to the infusion needle 2 under appropriately applied pressure, and “off”, which completely shuts the passage. In the “off” position the valve 6 prevents blood from the patient's vein from entering the conduit 4 and farther into the syringe when vacuum is in the syringe.
- Conduit star 8 which fluidly connects the syringe outlet 7 , infusion needle 2 and the saline reservoir 14 , is also connected to a conduit 11 , leading to a multi-port selection valve 15 .
- the multi-port valve 15 is designed to separately communicate the conduit 11 with a needle set 16 .
- the needles are adapted to further communicate with drug vials from a medication library 17 .
- the multi-port valve 15 may connect the syringe to a selected drug vial.
- the drug library 17 is disposed in a hermetic sterile department of a cooler 18 , preferably, a thermoelectric cooler.
- a needle set 16 is secured in an engaging mechanism 19 .
- a thermally insulating wall 20 is removed or punctured through by the needles during activation of the system.
- the engaging mechanism 19 moves the needle set along a rail 21 , a part of engaging mechanism 19 , forcing all needles to prick all rubber caps of multiple vials simultaneously and thus ensuring fluid communication of the conduit 11 with the drug library 17 .
- the needle set is propelled along the rail 21 by hand or automatically by an electro motor, not shown in FIG. 1.
- the syringe 9 is the main part of an automated IV pump 22 , which also includes an electric motor 23 and a worm mechanism 24 , transforming rotational motion of the motor into a translational push-pull motion of the piston 25 in the syringe 9 .
- the programmable control unit 3 of the system controls “on-off” positions of the valves 6 , 10 , 13 , 15 , the longitudinal position of the piston 25 in the syringe 9 , and the speed of its motion, defining the intravenous infusion rate.
- the control unit has several standard programs for priming the system, reconstitution of the drugs, preparing predetermined concentrations of drugs in saline solution, and their delivery in predetermined amounts and rates into the patient circulation.
- the control unit 17 can be reprogrammed remotely by a physician via the a modem connection such as through a phone line or the Internet.
- a modem connection such as through a phone line or the Internet.
- an Internet interface 26 with a phone connector 27 is provided.
- a battery with recharging circuitry is provided, which can be powered by any of standard voltages: 110, 220, 12 V.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
This invention provides an apparatus and method for emergency administration or self-administration of thrombolytic therapy in early stage of a heart attack. The apparatus includes a needle injector for making a venipuncture, a battery operated micro cooler for maintaining low temperature environment for vials with lyophilized thrombolytic and adjuvant drugs, a container with a diluent for reconstitution of the lyophilized drugs, a programmable infusion pump, and a microprocessor for controlling the process of infusion and recording the data. As the system is activated, said container becomes fluidly communicable with the infusion pump and vials with drugs in the cooler. Designed for autonomous execution of several schedules of infusion, it also can be controlled remotely by a qualified operator via an Internet interface.
Description
- This invention relates to medical devices and more particularly to devices and methods for thrombolytic therapy of coronary arteries for patients experiencing an early stage of acute myocardial infarction.
- Acute myocardial infarction is a major cause of mortality and morbidity in an atherosclerosis—prone contemporary society. Each year approximately 1.5 million Americans suffer a myocardial infarction, and more than 400,000 individuals will likely die from it this year. Few life threatening diseases are as common as acute myocardial infarction. Myocardial infarction is the morphologic manifestation of irreversible cell death in an area of the heart that is caused by a prolonged, and often abrupt, mismatch between the supply of the oxygen and nutrients in the blood and the metabolic needs of the myocardial cells. The most common cause of this condition is the sudden interruption of blood flow in a coronary artery by an occlusive thrombus formed in an area with atherosclerotic disease. A myocardial infarction is an evolving, dynamic event. A coronary occlusion results in ischemia that is initially reversible, but over time becomes irreversible. Necrosis of myocardium, or cardiac muscle, begins 20 to 30 minutes after total occlusion of the vessel. This “wave front of necrosis” proceeds through the ischemic part of the myocardium and is complete within 4-6 hours of occlusion. Later a scar is formed over the necrotic part of the myocardium. The area of myocardium affected by infarction does not contribute any more to the overall pumping function of the heart.
- To successfully salvage the myocardium, the blood flow though the occluded artery must be restored before the myocardium cells have been irreversibly destroyed. Restoration of the blood flow, or reperfusion, is more successful at the early stage of evolving infarction. Prompt therapy can make the difference between heart muscle death or salvage.
- The most common method of reperfusion heart muscle during a myocardial infarction is the use of medications that dissolve thrombi—thrombolytic agents. Thrombolytic agents, including streptokinase, urokinase, anisteplase, and tissue plasminogen activator (tPA) are extremely efficient in preventing disability and the death among people having heart attacks. About 80 percent of people having a heart attack who receive a thrombolytic agent within 2 hours of the onset of symptoms have reperfusion. Successful reperfusion reduces the size of the myocardial infarction and helps preserve the overall pumping function of the heart.
- There are several compelling reasons to start the thrombolytic therapy as early as possible. Probably, the best time for it is approximately 20-30 minutes after onset of symptoms, when no irreversible damage to the myocardium has been done yet. At this time the polymerization of fibrin in thrombus is still in progress and the thrombus is soft and easier to dissolve. This is because at this stage it is more permeable for the thrombolytic agents. The major mechanism of thrombolysis of totally occlusive thrombi is dragging the blood plasma with a thrombolytic agent in it through the body of thrombus by the blood pressure differential before and after the thrombus. Thus, early started thrombolytic therapy allows facilitates the faster dissolution of the thrombus. It is important also that for lysis of a very fresh thrombus that all thrombolytic agents are equally efficient. The tPA agent is about 10 times more expensive than streptokinase, but there is no difference in the time of dissolving of fresh thrombi.
- Thus, very early thrombolytic therapy promises a complete salvage of the myocardium with the preservation of the overall pumping function of the heart, and it can be performed with a cost effective choice of thrombolytic drug. Mortality and morbidity of the patients suffering a myocardial infarction can be drastically reduced.
- Whether or not thrombolytic treatment is undertaken or successful, additional treatment is usually required. Nitroglycerin is given either under the tongue or by vein to reduce symptoms by decreasing the heart's demand for oxygen and by improving the blood flow through coronary arteries as much as possible. Heart attacks can be very painful, so narcotics such as morphine are given when necessary. Medications such as beta-adrenergic blocking agents may be helpful for reducing pain and enhancing survival. Beta-adrenergic blockers make the heart beat more slowly and less forcefully, so it requires less oxygen. Blood clots can re-form in the coronary artery at the sites where thrombolysis has already dissolved the original blood clot. Thrombolytic drugs dissolve blood clots that already formed; anticoagulants prevent new blood clots from developing. A similar function is performed by antiplatelet medication like aspirin, which can be administered orally or intravenously.
- Both thrombolytic therapy and supportive care are available in emergency rooms in hospitals. A lot of effort has been spent to provide the treatment as soon as possible. Nevertheless, the shortest time that passes before the treatment starts is still about two hours. At this time some damage to the myocardium is already done, and the treatment strategy is to minimize it and relieve the symptoms associated with this damage.
- In many countries a special emergency mobile care paramedic unit has been introduced for cardiac patients with suspected myocardial infarction. With this “out-of-hospital” approach thrombolytic therapy can be delivered faster than in hospital emergency rooms. It is very promising way of improving cardiac care. The drawback of this approach is that the diagnosis and overall management of the patients by paramedics is not of the quality provided by highly qualified physicians in the emergency rooms in hospitals.
- It is desirable that the emergency care be selected, prescribed and managed by the patient's personal cardiologist, who is familiar with the patient's cardiac history and general state of health.
- It is desirable also to develop a method to provide a multiple medication therapy for cardiac patients suffering from a heart attack in its earliest stage, in the first 20-30 minutes after the onset of the symptoms. Such an early start would make real a new treatment strategy, the fundamental objective of which is the complete salvage of the myocardium and the preservation of 100% of its pumping function, rather than reducing to minimum the damage made in the first 2 hours.
- There have been many known devices and methods for intravenous infusion of drugs, particularly drugs in a dry form, or lyophilized drugs, ready for reconstitution to liquid state before the usage. As an example, U.S. Pat. No. 5,024,657, assigned to Baxter International, and many others in U.S. class 604/85. This device is intended for hospital use by a qualified nurse or physician. It is not automated and can't be used by a person with little or no medical training.
- It should be mentioned that a great number of contemporary drugs loose their activity within months of storage at room temperature. It is especially true for the protein based drugs, including thrombolytic agents. The system in accordance with the referred patent does not have a cooler and thus does not warrant the long-term efficiency of the drugs. It can not be held in a stand by state for a long period of time.
- Another example of prior art can be U.S. Pat. No. 5,609,572, issued to Volker Lang. In this patent a modular cassette infusion system for multiple infusions and automatic administration of medicaments is described. For infusion control the system utilizes a microprocessor, which has fixed program and manual programming steps and is compatible with the infusion equipment. It substantially reduces the work to be performed by nursing staff. The device described in this patent requires manual reconstitution of dry drugs and does not allow keeping the drug potent and ready for a long time. To operate the system and to make an intravenous (IV) puncture by a standard needle carrier a professional nurse is required. The system is not adapted for self-administration of thrombolytic therapy.
- An IV needle carrier assembly is described in U.S. Pat. No. 4,170,993. It includes a delta-shaped base plate and IV needle carrier—receiving barrel, secured to the base plate. An adhesion tape affixed to the base plate anchors the plate to the skin of the patient. The needle can be moved in two positions, rearward and forward. In the latter position it is placed for puncturing the vein. After establishing an IV access the base is affixed by the adhesion tape for the assembly to retain its place on the skin. This IV needle assembly is intended to be used by a medical professional and is not adapted to gaining an IV access by a patient himself.
- An object of the present invention is to provide an apparatus and method for intravenous infusion of thrombolytic agents and supportive medication as early as 20-30 minutes after the onset of the heart attack symptoms.
- Another object of the present invention is to provide an apparatus capable of being in a stand-by position continuously for several years.
- Yet another object of the invention is to provide numerous standard schedules of delivery of medications, enabling a cardiologist to select an appropriate care for covering the needs of different patients.
- Another object of the present invention is, in case of inability to promptly contact a personal cardiologist or other qualified physician, to provide a cardiac patient with an option to self-diagnose an acute myocardial infarction and self-administer the thrombolytic therapy.
- Another object of the present invention is to provide a simple and easy to use needle carrier adapted for gaining IV access by a patient himself or another person without special advanced medical training.
- Yet another object of the invention is to provide a low temperature environment for the library of medications ensuring preservation of their potency for several years.
- Yet another object of the present invention is to provide a library of medication for thrombolytic therapy and supportive care for the treatment of a heart attack. Provided medication can be in a lyophilized or liquid form.
- Another object of present invention is to provide to a personal cardiologist or other qualified physician remote access to the control of the apparatus via the Internet or other information network.
- Another object of the present invention is to provide an apparatus for IV infusion, that is highly automated and, after activation, does not require any intervention of an operator.
- Still another object is to make the system portable and battery powered, so it can be maintained in a stand by state at a residence, in a car, in an aircraft, or in the field.
- The fore mentioned objects are achieved by the present invention, which provides an apparatus and method for emergency treatment of a myocardial infarction. The apparatus comprises a library of medications, a highly automated infusion pump, controlled by a microprocessor, an intravenous needle, providing an access to the patient's circulatory system, a set of valves and conduits, providing fluid communication between the pump, the needle, the medications vials and a bag of solvent used for reconstitution of the lyophilized medications. These medications are placed into a sterile compartment, in which temperature is reduced to 4 C. or lower. This temperature guarantees protein thrombolytic drug stability during 3-5 years if the cooler is not off more than 1-3 months total.
- The invention is intended to be used in the out-of-hospital settings like a residence, a car, a passenger aircraft, a hotel, a nursing home and the like.
- This invention provides an opportunity to a patient himself to start the thrombolytic therapy right after the onset of cardiac pain, only 20-30 minutes after an occlusion in coronaries had been diagnosed (independently by the patient him/herself or after a consultation with a physician). To activate the system and start the therapy the patient should perform very simple operations with a highly automated infusion system. First, after activation the system reconstitutes the lyophilized drugs and primes itself by venting the air to avoid an air embolism. When the system is ready for infusion, it sends a message to the operator and waits for a command to start infusion. At that time the patient should gain an IV access by puncturing a vein on his/her wrist, thereby fluidly connecting the infusion apparatus with the patient's circulatory system. As soon as the access to the patient's vein is established, the thrombolytic and concomitant therapy can be started at any moment. As the treatment starts the system uses as a default a predetermined infusion schedule, preselected by a personal physician of the patient. The state of the patient during infusion can be evaluated by a physician via a phone line though conversation, or other diagnostic means like ECG with an Internet interface, capable of sending data to the physician. The system can be stopped at any moment and, depending on the state of the patient, the infusion schedule can be changed via the Internet by a qualified physician or by the operator (patient) directly. With the thrombolytic and supportive therapy in progress all efforts should be undertaken to transport the patient to an emergency room in a hospital, where the patient can be treated further by qualified cardiologists. The information about all medications infused into the patient's circulatory system, and the schedules of their infusion are stored in the data acquisition system of the apparatus and are available for the qualified personnel in the emergency room of the hospital.
- This invention is intended to be used by well-informed patients experiencing an early stage of a heart attack. Individuals who already had a heart attack, are good candidates for using the apparatus. The term well-informed patients means that these patients not only are familiar with the basics of the cardiovascular disease but also were instructed in details by their personal cardiologist how to use this apparatus, how to communicate with the physician during the onset of a heart attack, what symptoms are important for the correct diagnosis or self-diagnosis of his/her conditions, if by some reasons the contacts with a cardiologist are impossible. In this case the patient must rely upon his/her own judgments and an automated infusion of drugs which will be performed according to the schedules preselected by the patient's physician.
- The present invention provides thrombolytic therapy for cardiac patients at the earliest stage of a heart attack, before any necrosis of myocardium or other irreversible changes occur. Right after an occlusion of a coronary artery has happened, the thrombus is weak and is easier to dissolve. It requires less time and amount of thrombolytic agent for restoring patency of the occluded artery and thus results in lower chances of bleeding complications, the major side effect of thrombolytic therapy. In addition, at the early stage of thrombosis, there is no significant difference in efficiency between different thrombolytic drugs (SK or t-PA). So, an early thrombus can be efficiently dissolved by a cheaper streptokinase (SK), cost of which is about 10% of that of t-PA. The overall value of the present invention is provided by the ability of early TT to completely salvage patient's myocardium, resulting in significantly lower morbidity and mortality.
- The present invention is designated for use by emergency personal with limited or no medical training in nursing homes, passenger aircrafts and the like, and by well-informed high heart attack risk cardiac patients. The intended individual users should be cautiously screened by a qualified cardiologist before prescribing them an opportunity to buy a system and self-administering the thrombolytic drugs. Before activating the system and starting TT individual users have to diagnose a coronary artery occlusion relying upon their symptoms. The pain of an acute MI typically lasts for at least 30 min, it is unrelenting and does not respond to nitroglycerin. Pain that is not relieved by nitroglycerin or nifedipine challenge (ruling out coronary vasospasm) would indicate occlusive thrombus instead of unstable angina.
- The objects, features, and advantages of the present invention are evident for those skilled in the art from the following description of a preferred embodiment of the invention with reference to the accompanying drawings.
- FIG. 1 is an apparatus for out-of-hospital thrombolytic and supportive therapy.
- The present invention is schematically shown in the FIG. 1. A
needle carrier 1, which includes anIV needle 2, is fluidly connected via aconduit 4 to anoutlet 7 of asyringe 9.Hydrophilic filter 5 prevents accidentally trapped air bubbles from entering the patient circulation. One-way valve 6 separates theneedle conduit 4 from aconduit star junction 8, connected to thesyringe outlet 7. Thevalve 6 has two positions: “on”, which allows the liquid from thesyringe outlet 7 to flow to theinfusion needle 2 under appropriately applied pressure, and “off”, which completely shuts the passage. In the “off” position thevalve 6 prevents blood from the patient's vein from entering theconduit 4 and farther into the syringe when vacuum is in the syringe. - Another one-way “on-off”
valve 13 controls the passage of fluid from asaline diluent reservoir 14 via aconduit 12 to theconduit star 8. It also has two positions: in “on” position theconduit 12 is open and when vacuum is applied saline can be slicked into thesyringe outlet 7. In the “off” position theconduit 12 is shut off, and the fluid communication between thesaline reservoir 14 and the syringe is blocked. -
Conduit star 8, which fluidly connects thesyringe outlet 7,infusion needle 2 and thesaline reservoir 14, is also connected to aconduit 11, leading to amulti-port selection valve 15. Themulti-port valve 15 is designed to separately communicate theconduit 11 with a needle set 16. The needles are adapted to further communicate with drug vials from amedication library 17. By demand of thecontrol unit 3 themulti-port valve 15 may connect the syringe to a selected drug vial. Thedrug library 17 is disposed in a hermetic sterile department of a cooler 18, preferably, a thermoelectric cooler. A needle set 16 is secured in an engaging mechanism 19. A thermally insulatingwall 20 is removed or punctured through by the needles during activation of the system. - When the system is activated, the engaging mechanism19 moves the needle set along a
rail 21, a part of engaging mechanism 19, forcing all needles to prick all rubber caps of multiple vials simultaneously and thus ensuring fluid communication of theconduit 11 with thedrug library 17. The needle set is propelled along therail 21 by hand or automatically by an electro motor, not shown in FIG. 1. Thesyringe 9 is the main part of anautomated IV pump 22, which also includes anelectric motor 23 and aworm mechanism 24, transforming rotational motion of the motor into a translational push-pull motion of thepiston 25 in thesyringe 9. Theprogrammable control unit 3 of the system controls “on-off” positions of thevalves piston 25 in thesyringe 9, and the speed of its motion, defining the intravenous infusion rate. - The control unit has several standard programs for priming the system, reconstitution of the drugs, preparing predetermined concentrations of drugs in saline solution, and their delivery in predetermined amounts and rates into the patient circulation. The
control unit 17 can be reprogrammed remotely by a physician via the a modem connection such as through a phone line or the Internet. For this purpose anInternet interface 26 with aphone connector 27 is provided. Additionally, with advancing wireless technology, such remote programming could be accomplished through the use of wireless communication devices. A battery with recharging circuitry is provided, which can be powered by any of standard voltages: 110, 220, 12 V. - It will be obvious to those skilled in the art that many modifications may be made within the scope of the present invention without departing from the spirit of thereof, and the invention includes all such modifications.
- The present invention having thus been described, other modifications, alterations, or substitutions may now suggest themselves to those skilled in the art, all of which are within the spirit and the scope of the present invention. It is therefore intended that the present invention be limited only by the scope of the attached claims below.
Claims (7)
1. An apparatus for out-of-hospital thrombolytic therapy comprising: a. a library of medication in liquid or lyophilized form including a thrombolytic agent, adjuvant drugs for supportive care during heart attack and a diluent for reconstitution of drugs; b. an intravenous needle providing an access to the patient's circulatory system; c. a battery operated infusion pump with a set of conduits, on-off and multi-port valves fluidly communicable with the intravenous needle, the source of a diluent, and the vials with drugs in the library; d. a battery operated micro cooler adapted for keeping the medication library at reduced temperatures for preservation of their potency over a several year period; e. a microprocessor based control unit with a stored set of programs, designed to control operation of the infusion pump and valves to provide the priming of the system, drug reconstitution, and preprogrammed intravenous infusion of the thrombolytic agent and supportive drugs.
2. An apparatus for out-of-hospital thrombolytic therapy according to claim 1 , wherein said control unit is adapted for remote programming via the Internet, by a local operator, or by the patient.
3. An apparatus for out-of-hospital thrombolytic therapy according to claim 1 , which is portable.
4. An apparatus for out-of-hospital thrombolytic therapy according to claim 1 , wherein the temperature in the medication library is kept below 5 degree C.
5. An apparatus for out-of-hospital thrombolytic therapy according to claim 1 , wherein the thrombolytic agent and the schedule of infusion are preselected by a physician for the patient individually.
6. An apparatus for out-of-hospital thrombolytic therapy comprising: a. a thrombolytic agent in lyophilized form and a diluent for its reconstitution; b. an intravenous needle providing an access to the patient's circulatory system; c. an infusion pump or syringe; d. a battery operated micro cooler adapted for keeping the thrombolytic agent at reduced temperatures for preservation of its potency over a several year period.
7. A method of out-of-hospital thrombolytic therapy comprising: providing an apparatus including: a library of medication in liquid or lyophilized form including a thrombolytic agent, adjuvant drugs for supportive care during heart attack and a diluent for reconstitution of drugs; an intravenous needle providing an access to the patient's circulatory system; a battery operated infusion pump with a set of conduits, on-off and multi-port valves fluidly communicable with the intravenous needle, the source of a diluent, and the vials with drugs in the library; a battery operated micro cooler adapted for keeping the medication library at reduced temperatures for preservation of their potency over a several year period; a microprocessor based control unit with a stored set of programs, designed to control operation of the infusion pump and valves to provide the priming of the system, drug reconstitution, and preprogrammed intravenous infusion of the thrombolytic agent and supportive drugs; keeping said apparatus in stand by state continuously for long period of time until it is needed; activating the apparatus after onset of the symptoms of a heart attack, with the heart attack diagnosis confirmed or not confirmed by a physician; gaining an intravenous access to the patient's circulatory system by puncturing a vein with an intravenous needle provided with apparatus; and starting treatment.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/750,503 US20040162515A1 (en) | 2001-05-07 | 2003-12-31 | Apparatus and method for out-of-hospital thrombolytic therapy |
US11/285,123 US20060079860A1 (en) | 2001-05-07 | 2005-11-22 | Apparatus and method for out-of-hospital thrombolytic therapy |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/849,051 US6699230B2 (en) | 2000-05-10 | 2001-05-07 | Apparatus and method for out-of-hospital thrombolytic therapy |
US10/750,503 US20040162515A1 (en) | 2001-05-07 | 2003-12-31 | Apparatus and method for out-of-hospital thrombolytic therapy |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/849,051 Continuation US6699230B2 (en) | 2000-05-10 | 2001-05-07 | Apparatus and method for out-of-hospital thrombolytic therapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/285,123 Continuation US20060079860A1 (en) | 2001-05-07 | 2005-11-22 | Apparatus and method for out-of-hospital thrombolytic therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040162515A1 true US20040162515A1 (en) | 2004-08-19 |
Family
ID=32851363
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/849,051 Expired - Fee Related US6699230B2 (en) | 2000-05-10 | 2001-05-07 | Apparatus and method for out-of-hospital thrombolytic therapy |
US10/750,503 Abandoned US20040162515A1 (en) | 2001-05-07 | 2003-12-31 | Apparatus and method for out-of-hospital thrombolytic therapy |
US11/285,123 Abandoned US20060079860A1 (en) | 2001-05-07 | 2005-11-22 | Apparatus and method for out-of-hospital thrombolytic therapy |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/849,051 Expired - Fee Related US6699230B2 (en) | 2000-05-10 | 2001-05-07 | Apparatus and method for out-of-hospital thrombolytic therapy |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/285,123 Abandoned US20060079860A1 (en) | 2001-05-07 | 2005-11-22 | Apparatus and method for out-of-hospital thrombolytic therapy |
Country Status (1)
Country | Link |
---|---|
US (3) | US6699230B2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006124634A1 (en) * | 2005-05-16 | 2006-11-23 | Mallinckrodt Inc. | Multi-barrel syringe having integral manifold |
WO2007130809A2 (en) * | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
US20080177126A1 (en) * | 2007-01-01 | 2008-07-24 | Tate Leon J | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
WO2008135989A1 (en) * | 2007-05-02 | 2008-11-13 | Medimop Medical Projects Ltd | Automatic liquid drug preparation apparatus for the preparation of a predetermined dosage of liquid drug |
WO2012019641A1 (en) * | 2010-08-10 | 2012-02-16 | F. Hoffmann-La Roche Ag | Drug reconstitution and delivery device |
CN102655837A (en) * | 2009-12-23 | 2012-09-05 | 麦迪麦珀医疗工程有限公司 | Medical apparatus and single use kit including flow control device for use therewith for reconstitution and administration of liquid drug dosage |
WO2014121677A1 (en) * | 2013-02-08 | 2014-08-14 | Gong He | Electric multi-bottle infusion apparatus |
US9108047B2 (en) | 2010-06-04 | 2015-08-18 | Bayer Medical Care Inc. | System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors |
WO2016051390A1 (en) * | 2014-10-02 | 2016-04-07 | Equashield Medical Ltd. | Liquid transfer system |
USD954253S1 (en) | 2019-04-30 | 2022-06-07 | West Pharma. Services IL, Ltd. | Liquid transfer device |
USD956958S1 (en) | 2020-07-13 | 2022-07-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
US11918542B2 (en) | 2019-01-31 | 2024-03-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2377176B (en) * | 2001-06-30 | 2004-10-20 | John Leyshon Maddocks | Devices for administering material |
CA2426115A1 (en) * | 2003-04-18 | 2004-10-18 | Victor Gurewich | Methods, devices, and compositions for lysis of occlusive blood clots while sparing wound sealing clots |
ITMO20030201A1 (en) * | 2003-07-11 | 2005-01-12 | Hs Hospital Service Spa | SYSTEM OF INFUSION OF PHARMACOLOGICAL SOLUTIONS |
JP2005131007A (en) * | 2003-10-29 | 2005-05-26 | Nemoto Kyorindo:Kk | Medical fluid injection system |
WO2006030764A1 (en) * | 2004-09-14 | 2006-03-23 | Nemoto Kyorindo Co., Ltd. | Leakage detector |
WO2007081383A1 (en) * | 2006-01-06 | 2007-07-19 | Renal Solutions, Inc. | Dialysis machine with transport mode |
EP1976579B1 (en) * | 2006-01-06 | 2013-08-07 | Renal Solutions, Inc. | Dual purpose acute and home treatment dialysis machine |
US11497846B2 (en) | 2006-02-09 | 2022-11-15 | Deka Products Limited Partnership | Patch-sized fluid delivery systems and methods |
US11364335B2 (en) | 2006-02-09 | 2022-06-21 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US11027058B2 (en) | 2006-02-09 | 2021-06-08 | Deka Products Limited Partnership | Infusion pump assembly |
US12070574B2 (en) | 2006-02-09 | 2024-08-27 | Deka Products Limited Partnership | Apparatus, systems and methods for an infusion pump assembly |
US11478623B2 (en) | 2006-02-09 | 2022-10-25 | Deka Products Limited Partnership | Infusion pump assembly |
US9839743B2 (en) * | 2006-02-09 | 2017-12-12 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
EP1993636B2 (en) | 2006-02-09 | 2017-03-01 | Deka Products Limited Partnership | Peripheral systems |
RU2423153C2 (en) * | 2006-10-18 | 2011-07-10 | Терумо Кабусики Кайся | Medical device |
JP2010517700A (en) | 2007-02-09 | 2010-05-27 | デカ・プロダクツ・リミテッド・パートナーシップ | Automatic insertion assembly |
US8225616B2 (en) * | 2007-10-23 | 2012-07-24 | Kewl Innovations, Inc. | Portable medicine cooler having an electronic cooling controller and medicine efficacy indication circuitry and method of operation thereof |
WO2009088956A2 (en) | 2007-12-31 | 2009-07-16 | Deka Products Limited Partnership | Infusion pump assembly |
US8881774B2 (en) * | 2007-12-31 | 2014-11-11 | Deka Research & Development Corp. | Apparatus, system and method for fluid delivery |
MX338464B (en) | 2007-12-31 | 2016-04-15 | Deka Products Lp | Infusion pump assembly. |
US10080704B2 (en) | 2007-12-31 | 2018-09-25 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US8900188B2 (en) | 2007-12-31 | 2014-12-02 | Deka Products Limited Partnership | Split ring resonator antenna adapted for use in wirelessly controlled medical device |
US9456955B2 (en) * | 2007-12-31 | 2016-10-04 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US10188787B2 (en) | 2007-12-31 | 2019-01-29 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
CA2738389C (en) | 2008-09-15 | 2017-01-17 | Deka Products Limited Partnership | Systems and methods for fluid delivery |
EP2476446B1 (en) * | 2009-07-01 | 2018-08-15 | Fresenius Medical Care Holdings, Inc. | Drug delivery devices and related systems and methods |
CA2768011C (en) | 2009-07-15 | 2018-07-24 | Deka Products Limited Partnership | Apparatus, systems and methods for an infusion pump assembly |
CN104873389B (en) | 2009-07-29 | 2017-12-05 | Icu医学有限公司 | Fluid conveying device and application method |
CA3065396C (en) * | 2009-12-30 | 2022-11-15 | Caliber Therapeutics, Inc. | Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body |
JP5844280B2 (en) | 2010-01-22 | 2016-01-13 | デカ・プロダクツ・リミテッド・パートナーシップ | Method and system for shape memory alloy wire control |
WO2011097487A2 (en) * | 2010-02-05 | 2011-08-11 | Deka Products Limited Partnership | Infusion pump apparatus, method and system |
CN102198299B (en) * | 2010-03-23 | 2013-01-16 | 上海白塔医药科技有限公司 | Medical circulating type cooling injection pump |
US8272227B2 (en) * | 2010-08-04 | 2012-09-25 | Spx Corporation | System and method for accurately recharging an air conditioning system |
FR2969507B1 (en) * | 2010-12-24 | 2014-07-11 | Eveon | DEVICE FOR MIXING TWO CONSTITUENTS |
CA2825524C (en) | 2011-01-31 | 2021-03-23 | Fresenius Medical Care Holdings, Inc. | Preventing over-delivery of drug |
US9987406B2 (en) | 2011-02-08 | 2018-06-05 | Fresenius Medical Care Holdings, Inc. | Magnetic sensors and related systems and methods |
WO2012177798A2 (en) | 2011-06-20 | 2012-12-27 | Renaudia Medical, Llc | Distributed medication delivery system and method having autonomous delivery devices |
US10556063B2 (en) | 2011-06-20 | 2020-02-11 | Renaudia Medical, Llc | Distributed medication delivery using autonomous delivery device |
EP4218857A3 (en) | 2011-12-22 | 2023-10-25 | ICU Medical, Inc. | Fluid transfer devices and methods of use |
WO2013134519A2 (en) | 2012-03-07 | 2013-09-12 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
US9144646B2 (en) | 2012-04-25 | 2015-09-29 | Fresenius Medical Care Holdings, Inc. | Vial spiking devices and related assemblies and methods |
WO2015003145A1 (en) | 2013-07-03 | 2015-01-08 | Deka Products Limited Partnership | Apparatus, system and method for fluid delivery |
EP3073982B1 (en) | 2013-11-25 | 2020-04-08 | ICU Medical, Inc. | Methods and system for filling iv bags with therapeutic fluid |
ES2788697T3 (en) | 2014-11-03 | 2020-10-22 | Thrombolytic Science Llc | Methods and compositions for safe and effective thrombolysis |
US11357966B2 (en) * | 2015-04-23 | 2022-06-14 | B. Braun Medical Inc. | Compounding device, system, kit, software, and method |
CA3006951C (en) | 2015-12-04 | 2024-05-14 | Icu Medical, Inc. | Systems, methods, and components for transferring medical fluids |
USD851745S1 (en) | 2016-07-19 | 2019-06-18 | Icu Medical, Inc. | Medical fluid transfer system |
WO2018022640A1 (en) | 2016-07-25 | 2018-02-01 | Icu Medical, Inc. | Systems, methods, and components for trapping air bubbles in medical fluid transfer modules and systems |
US20180214668A1 (en) * | 2017-02-02 | 2018-08-02 | The Cleveland Clinic Foundation | Anti-air embolism systems and methods of using same |
WO2018232305A1 (en) | 2017-06-16 | 2018-12-20 | Thrombolytic Science, Llc | Methods and compositions for thrombolysis |
WO2019209963A1 (en) | 2018-04-24 | 2019-10-31 | Deka Products Limited Partnership | Apparatus and system for fluid delivery |
ES2968900T3 (en) * | 2018-05-11 | 2024-05-14 | Bristol Myers Squibb Co | Series Pluggable Drug Modules for Combinatorial Drug Delivery Devices |
US11590057B2 (en) | 2020-04-03 | 2023-02-28 | Icu Medical, Inc. | Systems, methods, and components for transferring medical fluids |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5531697A (en) * | 1994-04-15 | 1996-07-02 | Sims Deltec, Inc. | Systems and methods for cassette identification for drug pumps |
US5551850A (en) * | 1994-03-09 | 1996-09-03 | Baxter International Inc. | Pump chamber and valve assembly |
US5704223A (en) * | 1996-07-02 | 1998-01-06 | Emerging Technology Systems, L.L.C. | Thermoelectric medicine cooling bag |
US5776452A (en) * | 1994-03-30 | 1998-07-07 | Immuno Aktiengesellschaft | Thrombosis agent |
US6070761A (en) * | 1997-08-22 | 2000-06-06 | Deka Products Limited Partnership | Vial loading method and apparatus for intelligent admixture and delivery of intravenous drugs |
US6202708B1 (en) * | 1998-11-09 | 2001-03-20 | Sims Deltec, Inc. | Fillable cassette apparatus and method |
US6203528B1 (en) * | 1995-03-06 | 2001-03-20 | Baxter International Inc. | Unitary molded elastomer conduit for use with a medical infusion pump |
US6230501B1 (en) * | 1994-04-14 | 2001-05-15 | Promxd Technology, Inc. | Ergonomic systems and methods providing intelligent adaptive surfaces and temperature control |
US6241704B1 (en) * | 1901-11-22 | 2001-06-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US6551298B1 (en) * | 2000-11-21 | 2003-04-22 | Jack Y. Zhang | Controlled medicament security enclosure system |
US6669669B2 (en) * | 2001-10-12 | 2003-12-30 | Insulet Corporation | Laminated patient infusion device |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4178368A (en) * | 1971-09-30 | 1979-12-11 | Behringwerke Aktiengesellschaft | Method for the treatment of thromboembolism |
US4741736A (en) * | 1986-12-10 | 1988-05-03 | I-Flow Corporation | Programmable infusion pump |
US4850972A (en) * | 1987-01-16 | 1989-07-25 | Pacesetter Infusion, Ltd. | Progammable multiple pump medication infusion system with printer |
US5207642A (en) * | 1987-08-07 | 1993-05-04 | Baxter International Inc. | Closed multi-fluid delivery system and method |
US4950245A (en) * | 1988-07-08 | 1990-08-21 | I-Flow Corporation | Multiple fluid cartridge and pump |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5256157A (en) * | 1991-01-31 | 1993-10-26 | Baxter International Inc. | Automated infusion pump with replaceable memory cartridges |
US5116316A (en) * | 1991-02-25 | 1992-05-26 | Baxter International Inc. | Automatic in-line reconstitution system |
US5248300A (en) * | 1991-12-16 | 1993-09-28 | Abbott Laboratories | Ambulatory infusion system with spring-pressurized reservoir |
EP0649316B2 (en) * | 1992-10-15 | 2013-08-28 | The General Hospital Corporation | An infusion pump with an electronically loadable drug library |
CA2083555A1 (en) * | 1992-11-23 | 1994-05-24 | David H. Laing | Portable infusion device |
US5389078A (en) * | 1993-10-06 | 1995-02-14 | Sims Deltec, Inc. | Programmable infusion pump for administering medication to patients |
US5573506A (en) * | 1994-11-25 | 1996-11-12 | Block Medical, Inc. | Remotely programmable infusion system |
US5925016A (en) * | 1995-09-27 | 1999-07-20 | Xrt Corp. | Systems and methods for drug delivery including treating thrombosis by driving a drug or lytic agent through the thrombus by pressure |
US5807336A (en) * | 1996-08-02 | 1998-09-15 | Sabratek Corporation | Apparatus for monitoring and/or controlling a medical device |
US5885245A (en) * | 1996-08-02 | 1999-03-23 | Sabratek Corporation | Medical apparatus with remote virtual input device |
US5895371A (en) * | 1996-08-27 | 1999-04-20 | Sabratek Corporation | Medical treatment apparatus and method |
US6074366A (en) * | 1998-01-16 | 2000-06-13 | Tandem Medical Inc. | Medication delivery apparatus |
US6231560B1 (en) * | 1999-02-10 | 2001-05-15 | Baxter International Inc | Method and apparatus for automatically controlling the level of medication |
-
2001
- 2001-05-07 US US09/849,051 patent/US6699230B2/en not_active Expired - Fee Related
-
2003
- 2003-12-31 US US10/750,503 patent/US20040162515A1/en not_active Abandoned
-
2005
- 2005-11-22 US US11/285,123 patent/US20060079860A1/en not_active Abandoned
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6241704B1 (en) * | 1901-11-22 | 2001-06-05 | Sims Deltec, Inc. | Drug pump systems and methods |
US5551850A (en) * | 1994-03-09 | 1996-09-03 | Baxter International Inc. | Pump chamber and valve assembly |
US5776452A (en) * | 1994-03-30 | 1998-07-07 | Immuno Aktiengesellschaft | Thrombosis agent |
US6230501B1 (en) * | 1994-04-14 | 2001-05-15 | Promxd Technology, Inc. | Ergonomic systems and methods providing intelligent adaptive surfaces and temperature control |
US5531697A (en) * | 1994-04-15 | 1996-07-02 | Sims Deltec, Inc. | Systems and methods for cassette identification for drug pumps |
US6203528B1 (en) * | 1995-03-06 | 2001-03-20 | Baxter International Inc. | Unitary molded elastomer conduit for use with a medical infusion pump |
US5704223A (en) * | 1996-07-02 | 1998-01-06 | Emerging Technology Systems, L.L.C. | Thermoelectric medicine cooling bag |
US6070761A (en) * | 1997-08-22 | 2000-06-06 | Deka Products Limited Partnership | Vial loading method and apparatus for intelligent admixture and delivery of intravenous drugs |
US6202708B1 (en) * | 1998-11-09 | 2001-03-20 | Sims Deltec, Inc. | Fillable cassette apparatus and method |
US6551298B1 (en) * | 2000-11-21 | 2003-04-22 | Jack Y. Zhang | Controlled medicament security enclosure system |
US6669669B2 (en) * | 2001-10-12 | 2003-12-30 | Insulet Corporation | Laminated patient infusion device |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080167621A1 (en) * | 2005-05-16 | 2008-07-10 | Wagner Gary S | Multi-Barrel Syringe Having Integral Manifold |
WO2006124634A1 (en) * | 2005-05-16 | 2006-11-23 | Mallinckrodt Inc. | Multi-barrel syringe having integral manifold |
WO2007130809A2 (en) * | 2006-05-06 | 2007-11-15 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
WO2007130809A3 (en) * | 2006-05-06 | 2008-03-20 | Volodymyr Brodskyy | An automatic injectable drug mixing device |
US9913941B2 (en) * | 2007-01-01 | 2018-03-13 | Bayer Healthcare Llc | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
US20080177126A1 (en) * | 2007-01-01 | 2008-07-24 | Tate Leon J | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
US20150335821A1 (en) * | 2007-01-01 | 2015-11-26 | Bayer Medical Care Inc | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
US9056164B2 (en) * | 2007-01-01 | 2015-06-16 | Bayer Medical Care Inc. | Radiopharmaceutical administration methods, fluid delivery systems and components thereof |
WO2008135989A1 (en) * | 2007-05-02 | 2008-11-13 | Medimop Medical Projects Ltd | Automatic liquid drug preparation apparatus for the preparation of a predetermined dosage of liquid drug |
US20100087786A1 (en) * | 2007-05-02 | 2010-04-08 | Medimop Medical Projects Ltd. | Automatic Liquid Drug Preparation Apparatus for the Preparation of a Predetermined Dosage of Liquid Drug |
US8316898B2 (en) | 2007-05-02 | 2012-11-27 | Medimop Medical Projects Ltd. | Automatic liquid drug preparation apparatus for the preparation of a predetermined dosage of liquid drug |
CN102655837A (en) * | 2009-12-23 | 2012-09-05 | 麦迪麦珀医疗工程有限公司 | Medical apparatus and single use kit including flow control device for use therewith for reconstitution and administration of liquid drug dosage |
US8597232B2 (en) * | 2009-12-23 | 2013-12-03 | Medimop Medical Projects, Ltd. | Medical apparatus and single use kit including linear flow control device for use therewith for reconstitution and administration of liquid drug dosage |
US20120271229A1 (en) * | 2009-12-23 | 2012-10-25 | Medimop Medical Projects Ltd. | Medical apparatus and single use kit including linear flow control device for use therewith for reconstitution and administration of liquid drug dosage |
US9463335B2 (en) | 2010-06-04 | 2016-10-11 | Bayer Healthcare Llc | System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors |
US9108047B2 (en) | 2010-06-04 | 2015-08-18 | Bayer Medical Care Inc. | System and method for planning and monitoring multi-dose radiopharmaceutical usage on radiopharmaceutical injectors |
WO2012019641A1 (en) * | 2010-08-10 | 2012-02-16 | F. Hoffmann-La Roche Ag | Drug reconstitution and delivery device |
CN103079606A (en) * | 2010-08-10 | 2013-05-01 | 弗·哈夫曼-拉罗切有限公司 | Drug reconstitution and delivery device |
WO2014121677A1 (en) * | 2013-02-08 | 2014-08-14 | Gong He | Electric multi-bottle infusion apparatus |
WO2016051390A1 (en) * | 2014-10-02 | 2016-04-07 | Equashield Medical Ltd. | Liquid transfer system |
EP3200745A4 (en) * | 2014-10-02 | 2019-09-11 | Equasheld Medical Ltd. | Liquid transfer system |
US11357702B2 (en) | 2014-10-02 | 2022-06-14 | Equashield Medical Ltd. | Liquid transfer system |
US11918542B2 (en) | 2019-01-31 | 2024-03-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
USD954253S1 (en) | 2019-04-30 | 2022-06-07 | West Pharma. Services IL, Ltd. | Liquid transfer device |
US11484470B2 (en) | 2019-04-30 | 2022-11-01 | West Pharma. Services IL, Ltd. | Liquid transfer device with dual lumen IV spike |
US11786442B2 (en) | 2019-04-30 | 2023-10-17 | West Pharma. Services IL, Ltd. | Liquid transfer device with dual lumen IV spike |
USD1043974S1 (en) | 2019-04-30 | 2024-09-24 | West Pharma. Services IL, Ltd. | Liquid transfer device |
USD956958S1 (en) | 2020-07-13 | 2022-07-05 | West Pharma. Services IL, Ltd. | Liquid transfer device |
Also Published As
Publication number | Publication date |
---|---|
US20020045856A1 (en) | 2002-04-18 |
US20060079860A1 (en) | 2006-04-13 |
US6699230B2 (en) | 2004-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6699230B2 (en) | Apparatus and method for out-of-hospital thrombolytic therapy | |
Braunwald | The aggressive treatment of acute myocardial infarction. | |
Gacioch et al. | Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management | |
Catanese et al. | Outpatient left ventricular assist device support: a destination rather than a bridge | |
CN106535954B (en) | Device for providing a resuscitation or pause state in cardiac arrest | |
US5405362A (en) | Interactive external defibrillation and drug injection system | |
JPH069610B2 (en) | Initiating device for reperfusion procedure in case of symptoms of heart attack | |
JP2003521260A (en) | Cardiovascular support control system | |
CN108601608A (en) | The device and method of emergency treatment heart arrest | |
US11577058B2 (en) | Cardiopulmonary resuscitation catheter and related systems and methods | |
DeRose Jr et al. | Implantable left ventricular assist devices: an evolving long-term cardiac replacement therapy | |
Jorde et al. | PREVENTion of non-surgical bleeding by management of HeartMate II patients without anti-platelet therapy (PREVENT II) trial | |
Rikkers | Definitive therapy for variceal bleeding: a personal view | |
Sheldon et al. | High-technology in home care: an overview of intravenous therapy | |
Bolton et al. | Removal of Acute Coronary Thrombus With Fibrinolysin—In Vivo Experiment: A Preliminary Report on the Use of Fibrinolytic Agents in the Treatment of Acute Thrombosis | |
US20210128821A1 (en) | Emergency medical intervention device | |
Md et al. | Prolonged selective urokinase infusion in totally occluded coronary arteries and bypass grafts: two case reports | |
Tsai et al. | Presumed pulmonary embolism following power-pulse spray thrombectomy of upper extremity venous thrombosis | |
US20140142548A1 (en) | Systems, devices and methods for resuscitation | |
MANNING et al. | 13 Selective Aortic Arch Perfusion | |
US20210205523A1 (en) | Catheter Clearance Device and Method of Use | |
US20240148950A1 (en) | Dialysis catheter clearance device and associated method | |
US20210205578A1 (en) | Catheter clearance device and method of use | |
CN214762627U (en) | Internal mammary artery injection device used in coronary artery bypass grafting operation | |
Dukovcic et al. | Percutaneous cardiopulmonary support for high-risk angioplasty |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |